Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care

Launched by LINKOEPING UNIVERSITY · Apr 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new tool called Dermalyser, which uses artificial intelligence (AI) to help doctors in primary care better identify skin cancer. While AI has shown promise in detecting skin cancer in previous studies, this trial aims to see how well it works in real-life settings, specifically in primary care clinics where most patients get their skin checked. The study will compare the accuracy of skin cancer diagnoses made with and without the help of Dermalyser, involving around 3,000 participants across several countries.

To be eligible for the trial, participants should be adults aged 65 to 74 who are visiting a primary care facility to have one or more skin lesions checked for cancer. Those with darker skin types (Fitzpatrick skin types V and VI) will not be included in the study. Participants can expect to be part of either a group that uses the Dermalyser tool during their evaluation or a group that follows the standard procedure without it. The goal is to see if using Dermalyser can help doctors catch skin cancer earlier and reduce unnecessary referrals to specialists for benign (non-cancerous) skin issues. This trial is not yet recruiting participants, but it has the potential to improve skin cancer detection in primary care settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients attending a primary care facility in order to have one or more skin lesions checked for skin cancer, or patients presenting with one or more skin lesions raising suspicion of skin cancer when noticed by the primary care physician.
• • Willingness and ability to provide informed consent.
• Exclusion Criteria:
• • Individuals with skin type V and VI according to the Fitzpatrick's scale (darker brown or black coloured skin)